Clinical trial
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in…
NCT00085644 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00085644 |
|---|---|
| Title | Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis |
| Official title | A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis |
| Acronym | ATLAS |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ankylosing Spondylitis |
| Intervention type | Biological |
| Interventions | adalimumab (D2E7), placebo |
| Enrollment | 315 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Jul 1, 2009 |
| First posted | Jun 16, 2004 |
| Last update posted | Apr 21, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: